Loading company…
ID 404578051 · FY 2023–2024 · 2 years
Subsidiary of შეზღუდული პასუხისმგებლობის საზოგადოება Quest 100 Biosciences LLC (100.0%)
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Ratio | 2023 | 2024 |
|---|---|---|
| Margins | ||
| Gross Margin | 40.3% | 87.4% |
| EBITDA Margin | -3.6% | 25.9% |
| EBITDAR | -50 | 951 |
| EBITDAR Margin | -3.6% | 29.7% |
| EBIT Margin | -8.5% | 21.3% |
| Net Profit Margin | -3.6% | 25.8% |
| Operating Expense % of Sales | 43.9% | 61.6% |
| Returns | ||
| Return on Assets (ROA) | -3.4% | 54.0% |
| Return on Equity (ROE) | N/A | 101.6% |
| ROIC [EBIT / Invested Capital] | -835.3% | 76.4% |
| Leverage & liquidity | ||
| Debt-to-Assets | 1.7% | 9.2% |
| Debt-to-Equity | -10.46x | 0.17x |
| Debt-to-EBITDA | N/A | 0.17x |
| Equity-to-Assets | -0.2% | 53.2% |
| Net Debt | 16 | 81 |
| Cash & Equivalents | 9 | 61 |
| Total Debt | 25 | 141 |
| Efficiency & working capital | ||
| Inventory Turnover | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A |
| Receivables Turnover | 10.78x | 19.76x |
| Days Sales Outstanding (DSO) | 33.9 | 18.5 |
| Payables Turnover | 0.90x | 29.07x |
| Days Payable Outstanding (DPO) | 407.5 | 12.6 |
| Cash Conversion Cycle | -373.6 days | 5.9 days |
| Asset Turnover | 0.93x | 2.10x |
| Cash flow & dividends | ||
| Operating Cash Flow | 5 | 52 |
| Free Cash Flow (OCF − Capex proxy) | 5 | 52 |
| Cash Conversion (OCF / EBITDA) | N/A | 6.3% |
| Dividends Declared | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in ₾ '000. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).